Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine and DLI in Relapsed MDS or AML After Allo-SCT
NCT05226455Phase 2Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Dose-finding study at 28 days. Started Nov 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05226455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226455.